IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 5, 2013, Pages 861-866

  Holmes, Jacinta A ^a   Nguyen, Tin ^a   Ratnam, Dilip ^b   Heerasing, Neel M ^b   Tehan, Jane V ^a   Bonanzinga, Sara ^c   Dev, Anouk ^b   Bell, Sally ^a   Pianko, Stephen ^b   Chen, Robert ^a   Visvanathan, Kumar ^b   Hammond, Rachel ^c   Iser, David ^a   Rusli, Ferry ^b   Sievert, William ^b   Desmond, Paul V ^a   Bowden, D Scott ^c   Thompson, Alexander J ^a,c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hepatitis B; IL28B genotype; Pegylated interferon; Treatment outcome

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME;

EID: 84876999254     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12110     Document Type: Article

References (34)

1. World Health Organization. Hepatitis B fact sheet no. 204. Cited 12 Apr 2012. Available from URL: http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11: 97-107.
3. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1956.
4. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin. Liver Dis. 2006; 26: 153-161.
5. van Zonneveld M, Honkoop P, Hansen BE etal. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-810.
6. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-1531.
7. Zoutendijk R, Reijnders JG, Zoulim F etal. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2012 [epub ahead of print].
8. Brook MG, McDonald JA, Karayiannis P etal. Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989; 30: 1116-1122.
9. Buster EH, Hansen BE, Lau GK etal. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-2009.
10. Ratnam D, Dev A, Nguyen T etal. The efficacy and tolerability of pegylated interferon-alpha-2a in chronic hepatitis B: a multicenter clinical experience. J. Gastroenterol. Hepatol. 2012; 27: 1447-1453.
11. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 1100-1104.
13. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
14. Sonneveld MJ, Wong VW, Woltman AM etal. Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 42: 513-520.
15. de Niet A, Takkenberg RB, Benayed R etal. Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with peg interferon alfa-2a and adefovir. Scand. J. Gastroenterol. 2012; 47: 475-481.
16. Tseng TC, Yu ML, Liu CJ etal. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir. Ther. 2011; 16: 629-637.
17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
18. Hansen BE, Buster EH, Steyerberg EW etal. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J. Med. Virol. 2010; 82: 1135-1142.
19. Rijckborst V, Hansen BE, Ferenci P etal. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J. Hepatol. 2012; 56: 1006-1011.
20. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
21. Lau GK, Piratvisuth T, Luo KX etal. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-2695.
22. Marcellin P, Lau GK, Bonino F etal. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004; 351: 1206-1217.
23. Halfon P, Bourliere M, Ouzan D etal. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C genotype 1 virus. Eur. J. Gastroenterol. Hepatol. 2011; 23: 931-935.
24. Lampertico P, Vigano M, Cheroni C etal. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B. Hepatology 2012; doi:10.1002/hep.25749 [epub ahead of print].
25. Mangia A. Lack of association between IL28B variants and HBsAg clearance after interferon treatment. J. Hepatol. 2011; 54: S525.
26. Kamatani Y, Wattanapokayakit S, Ochi H etal. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat. Genet. 2009; 41: 591-595.
27. Li W, Jiang Y, Jin Q etal. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int. 2011; 31: 1118-1126.
28. Martin MP, Qi Y, Goedert JJ etal. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J. Infect. Dis. 2010; 202: 1749-1753.
29. Thompson AJ, Nguyen T, Iser D etal. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944.
30. Thompson AJ, Ayres A, Yuen L etal. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J. Gastroenterol. Hepatol. 2007; 22: 1078-1085.
31. Nguyen T, Thompson AJ, Bowden S etal. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J. Hepatol. 2010; 52: 508-513.
32. Bell SJ, Lau A, Thompson A etal. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. J. Clin. Virol. 2005; 32: 122-127.
33. Patterson SJ, George J, Strasser SI etal. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60: 247-254.
34. Holmes JA, Nguyen T, Bell SJ etal. Outcome of a large single centre cohort of patients with chronic hepatitis B treated with Lamivudine. J. Gastroenterol. Hepatol. 2010; 25: A134.